Opportunities & Solicitations

How Does This Work?

JPM-MCS offers funding opportunities to MCDC members through solicitations called Requests for Prototype Proposals (RPPs). The RPPs offer MCDC members the opportunity to propose prototype technologies to the technology requirements in each solicitation’s objective or sub-objective area. Active and Closed solicitations are listed below.


If you are not a MCDC member and wish to become one, please click here for instructions.

INTENT TO ANNOUNCE

MCDC-RPP-TBD

Ebola Vaccine Prototype Manufacture

The project includes white paper and full proposal submission

Active Solicitations
RPP Release # (Date) Requirement Requiring Office Submission Type Submission Due Date
RPP-19-04
(12/19/2018)
PRE-19-04: Ebola Vaccine Prototype JPM-MCS Full Proposal 2/27/2019
12:00 Noon ET
RPP-19-02
(12/4/2018)
TRE/PRE-19-02-02: Development and Testing of a Rapid Response Antibody (Ab) Platform System and the Accelerated Development of a Safe and Efficacious Prototype Medical Countermeasure (MCM) Against a Biodefense Threat of Interest JPM-MCS Whitepaper
Full Proposal
12/19/2018
12:00 Noon ET
2/1/2019
12:00 Noon ET

*Only MCDC Members in good standing can submit whitepapers and proposals in response to solicitations. Please log-in to the MCDC Members Only Site to view complete solicitation information. If you do not have a username and password, please click here to request access.

 

 

Project Status

* Indicates Awardees who were pulled from the Basket

RPP Release # (Date)RequirementRequiring OfficeAwardeeAward DateAward Ceiling
RPP-16-01 (6/22/2016)16-01 Fill/Finish of Venezuelan Equine Encephalitis (VEE) virus like particle (VLP) Bulk Drug ProductJPEO-CBRND
JPM MCS
SRI International12/8/2016$660,715
RPP-16-01 (6/22/2016)16-02 Development of Monoclonal Antibody Medical Countermeasures against Aerozolized Botulinum Toxin Serotypes A and B JPEO-CBRND
JPM MCS
Ology Bioservices9/30/2016$39,820,156
RPP-16-02 (7/15/2016)16-03 Development of a Dual Drug Delivery Device (D4) AutoinjectorJPEO-CBRND
JPM MCS
Emergent BioSolutions7/25/2017$23,145,596
RPP-16-02 (7/15/2016)16-05 Venezuelan equine encephalitis (VEE) Monovalent VLP Phase I Clinical StudyJPEO-CBRND
JPM MCS
SRI International2/3/2017$4,922,193
RPP-17-01 (1/13/2017)17-02 Development of Efficacious Antiviral Countermeasures JPEO-CBRND
JPM MCS
*Mapp BioPharmaceuticals11/7/2017$40,831,616
RPP-17-02 (2/13/2017)17-04 Development of Multi-Target Single-Vector Vaccine Prototype against aerosolized Venezuelan Equine Encephalitis Virus (VEEV)JPEO-CBRND
JPM MCS
Bavarian Nordic3/16/2018$35,894,256
RPP-17-02 (2/13/2017)17-05 Man-Portable Diagnostics System (MPDS)JPEO-CBRND
JPM MCS
MRI Global9/1/2017$36,364,633
RPP-17-03(6/17/2017)17-07 Man-Portable Diagnostics System (MPDS) – Expanded ScopeJPEO-CBRND
JPM MCS
Cepheid8/24/2018$56,362,300
RPP-17-03(6/17/2017)17-08 Chemical Exposure In Vitro Diagnostics (ChemDx)JPEO-CBRND
JPM MCS
MRI Global10/10/2018$9,653,670
RPP-18-01(10/19/2017)18-01 Rapid Single-molecule-based Diagnostic Platform Assessment of Pathogen Susceptibility to Anti-microbial AgentDTRA JSTOCalifornia Institute of Technology12/4/2018$3,387,096
RPP-18-01(10/19/2017)18-01 Rapid Single-molecule-based Diagnostic Platform Assessment of Pathogen Susceptibility to Anti-microbial AgentDTRA JSTOGeneral Electric Co.12/13/2018$5,997,583
RPP-18-01(10/19/2017)18-03 Late Discovery and Development of Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve AgentsDTRA JSTOLeidos8/16/2018$10,966,574
RPP-18-02 (1/10/2018)18-04 Relevant Large Animal Model Prototypes for Organophosphorus (OP) Nerve Agent (NA) Intoxication and Therapeutic EvaluationsJPEO-CBRND JPM MCSSciTech Services9/12/2018$235,797
RPP-18-04 (4/5/2018)18-15 Point-of-Care Diagnostics to identify the Causative Agents for Melioidosis and the PlagueDTRA JSTOInbios International8/27/2018$4,436,864
RPP-18-04 (4/5/2018)18-15 Point-of-Care Diagnostics to identify the Causative Agents for Melioidosis and the PlagueDTRA JSTOBrimrose Technology Corp9/24/2018$1,319,680